|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of CYP2C19 Polymorphisms With Clopidogrel Reactivity and Clinical Outcomes in Chronic Ischemic Stroke.
|
31006731 |
2019 |
|
Ischemic stroke
|
0.100 |
Biomarker
|
disease |
BEFREE |
The proportions of CYP2C19 poor metabolizers within NS group and each IS group with disparate etiology are similar (NS 73 [13.1%]; LAA 44 [14.2%], p = 0.623; CE 26 [14.0%], p = 0.541; SVO 38 [13.3%], p = 0.443).
|
30932939 |
2019 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 30-day incidence of major adverse cardiovascular events, the composite of cardiovascular death, nonfatal myocardial infarction, and ischemic stroke were significantly higher in AA homozygotes than in non-AA homozygotes (adjusted hazard ratio, 2.78; 95% CI, 1.13-6.82; P=0.026), irrespective of CYP2C19*2 loss-of-function polymorphism and known outcome predictors including age, sex, smoking, and diabetes mellitus.
|
31018667 |
2019 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Even heterozygous CYP2C19*2 allele carriers among Caucasian patients after ischemic stroke had a higher risk of major adverse clinical events.
|
29509167 |
2018 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the association between CYP2C19*2 variants and END, and the effectiveness of antiplatelet therapy for prevention of END according to CYP2C19*2 genotypes in patients with ischemic stroke (IS).
|
30128710 |
2018 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients.
|
29804161 |
2018 |
|
Ischemic stroke
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We consecutively enrolled 375 patients with IS after they received clopidogrel therapy, and venous blood samples were subjected to genotyping allelic variants of genes modulating clopidogrel absorption (ATP binding cassette subfamily B1, ABCB1), metabolic activation (cytochrome P450[CYP] 3A and CYP2C19), and biologic activity (platelet membrane receptor [ P2Y12, P2Y1)], and glycoprotein IIIa [ GPIIIa]) and statistically analyzing their interactions with clopidogrel sensitivity (CS) and adverse events, risk of IS recurrence, myocardial infarction, and death during 6 months of follow-up.
|
27233747 |
2017 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events than noncarriers among patients with ischemic stroke or TIA treated with clopidogrel.
|
27806998 |
2017 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Comparison of Triflusal and Clopidogrel Effects in Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping (MAESTRO) study will investigate the effect of antiplatelet agents based on CYP2C19 polymorphisms in secondary prevention of ischemic stroke.
|
26763917 |
2016 |
|
Ischemic stroke
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19*2 and CYP2C19*3 had a significant impact on clopidogrel response, but was not associated with ischemic events during 1 year of follow-up in patients with acute ischemic stroke.
|
26177117 |
2015 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, carriage of the CYP2C19 LOF allele has significant influence on clopidogrel response and prognosis in patients with ischemic stroke.
|
25489921 |
2015 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese.
|
25030528 |
2014 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In clinical practice,LCR and CYP2C19 gene polymorphism should be assessed in NCIS patients receiving clopidogrel treatment.
|
25457586 |
2014 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
|
23640828 |
2013 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with non-carriers of the CYP2C19 variant allele, the carriers were found to have an increased risk of adverse clinical events (OR 1.50, 95% CI 1.21-1.87; P=0.0003), myocardial infarction (OR 1.62, 95% CI 1.35-1.95; P<0.00001), stent thrombosis (OR 2.08, 95% CI 1.67-2.60; P<0.00001), ischaemic stroke (OR 2.14, 95% CI 1.36-3.38; P=0.001) and repeat revascularization (OR 1.35, 95% CI 1.10-1.66; P=0.004), but not of mortality (P=0.500) and bleeding events (P=0.930).
|
24080325 |
2013 |